Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
daratumumab + hyaluronidase-fihj + dexamethasone
- Development stage
- Phase 2
- Lead developer
- Johnson & Johnson
- Modality
- Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules, Therapeutic Enzymes → Recombinant Proteins and Enzymes, Monoclonal Antibodies → Antibody-Based Therapeutics
- Administration
- Subcutaneous
01
Overview
Daratumumab + hyaluronidase-fihj + dexamethasone is a combination therapeutic regimen primarily used for the treatment of multiple myeloma and light chain (AL) amyloidosis. The regimen is anchored by **Darzalex Faspro**, a subcutaneous formulation containing daratumumab, a human IgG1 monoclonal antibody targeting CD38, and hyaluronidase-fihj, a recombinant human hyaluronidase enzyme that facilitates subcutaneous delivery by temporarily increasing tissue permeability. Daratumumab exerts its anti-tumor effects through complement-dependent cytotoxicity (CDC), antibody-dependent cell-mediated cytotoxicity (ADCC), antibody-dependent cellular phagocytosis (ADCP), and the induction of apoptosis. Dexamethasone, a potent corticosteroid, acts synergistically with daratumumab to enhance malignant cell death and is also utilized to mitigate potential injection-related reactions. This combination is often further combined with other agents such as lenalidomide, bortezomib, or pomalidomide in various lines of therapy.
- Other names
- subcutaneous daratumumab and dexamethasoneDarzalex Faspro and dexamethasoneDd SC
02
Targets
CD38 (Cluster of Differentiation 38)GR (Glucocorticoid receptor)
Beyond the preview
Go deeper on daratumumab + hyaluronidase-fihj + dexamethasone.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on daratumumab + hyaluronidase-fihj + dexamethasone.